WebCSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. WebApr 14, 2024 · Natixis Advisors L.P. lessened its position in shares of Carlisle Companies Incorporated (NYSE:CSL - Get Rating) by 17.0% in the fourth quarter, according to the …
If I’d invested $1,000 in CSL shares 24 years ago, here’s how much …
WebApr 14, 2024 · Investors of record on Friday, February 17th were given a $0.75 dividend. This represents a $3.00 annualized dividend and a dividend yield of 1.42%. The ex-dividend date of this dividend was ... WebCarlisle Companies Incorporated (NYSE:CSL) today announced its second quarter 2024 financial results. Reported consolidated second quarter revenue of $1.2 billion, up 22% from second quarter 2024 Delivered second quarter diluted EPS of $1.77; adjusted diluted EPS of $2.16 Repurchased 643 thousand shares for $116 million, 1.6 million shares for $266 … order georgia peaches
Carlisle Companies Reports Second Quarter Earnings
Web1 day ago · The second segment, CSL Seqirus (19% of FY22 revenue), was acquired by CSL in 2015 and is the second-largest influenza business in the world. Although CSL … Web14 hours ago · An investor buying $6,000 worth of CSL shares in April 2024 likely would have walked away with 37 stocks – paying $159.88 apiece – and approximately $85 … WebMar 5, 2024 · But investors buying CSL today can reasonably expect 12%-18% growth and 18x-21.5x earnings… with a five-year consensus return potential range of 9%-16% CAGR. order gevalia coffee online